R. Franks

Improved drug-like properties of therapeutic proteins by directed evolution

Greg Dean, Andrew Buchanan, R. Minter, 2012, Protein engineering, design & selection : PEDS.

Expression and characterisation of human and rat CRF2α receptors

P. Carnell, R. Mackenzie, R. Franks, 1999 .

[125i]Neurokinin A labels pharmacologically distinct populations of NK2 binding sites in hamster and rabbit urinary bladder

S. Guard, R. Franks, K. Watling, 1993 .

Distribution of terminal deoxynucleotidyl transferase and purine degradative and synthetic enzymes in subpopulations of human thymocytes.

G. Janossy, A. Hoffbrand, D. Ma, 1982, Journal of immunology.

Subcellular localization of enterokinase in human duodenal mucosa.

R. Franks, R. Lobley, R. Holmes, 1977, Clinical science and molecular medicine.

On the presence of NK2 receptor subtypes in peripheral and central tissues

R. Zarnegar, S. Guard, J. Krause, 1993, Regulatory Peptides.

Sequential chemoimmunotherapy with cisplatin, interleukin-2, and interferon alfa-2a for metastatic melanoma.

C. Borel, L. Thill, D. Khayat, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Recombinant Newcastle Disease Virus Immunotherapy Drives Oncolytic Effects and Durable Systemic Antitumor Immunity

R. Wilkinson, H. Jin, Xing Cheng, 2021, Molecular Cancer Therapeutics.